ONCY · Insider Trading
Oncolytics Biotech, Inc. Common Shares
Every open-market purchase and sale reported by ONCY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-03 | Deborah Margaret Brown | Director | A | +30,000 deriv. | — |
| 2026-06-03 | Jonathan Rigby | Director | A | +30,000 deriv. | — |
| 2026-06-03 | Patricia S Andrews | Director | A | +30,000 deriv. | — |
| 2026-06-03 | Jared Kelly | Chief Executive Officer | A | +755,000 deriv. | — |
| 2026-06-03 | Wayne Pisano | Director | A | +30,000 deriv. | — |
| 2026-06-03 | Allison Hagerman | Chief Technology Officer | A | +260,000 deriv. | — |
| 2026-06-03 | Kirk Look | Chief Financial Officer | A | +260,000 deriv. | — |
| 2026-06-03 | Stephen C. Glover | Director | A | +96,000 deriv. | — |
| 2026-06-03 | John Bearden McAdory | Chief Operating Officer | A | +145,000 deriv. | — |
| 2026-06-03 | Bernd R. Seizinger | Director | A | +30,000 deriv. | — |
| 2026-06-03 | Thomas Charles Heineman | Chief Medical Officer | A | +260,000 deriv. | — |
| 2026-06-03 | Angela Holtham | Director | A | +30,000 deriv. | — |
| 2026-06-03 | Andrew Aromando | Chief Business Officer | A | +260,000 deriv. | — |
| 2026-06-03 | James T. Parsons | Director | A | +30,000 deriv. | — |
| 2026-03-13 | Jared Kelly | Chief Executive Officer | Buy | +5,050 | +$4.85K |
| 2026-03-13 | James T. Parsons | Director | Buy | +10,000 | +$10.30K |
| 2026-02-13 | Andrew Aromando | Chief Business Officer | Buy | +29,600 | +$25.42K |
| 2026-02-13 | Thomas Charles Heineman | Chief Medical Officer | Buy | +12,132 | +$10.03K |
| 2026-02-13 | Deborah Margaret Brown | Director | Buy | +25,000 | +$21.24K |
| 2026-02-13 | Bernd R. Seizinger | Director | Buy | +100,000 | +$83.45K |
| 2026-02-13 | Wayne Pisano | Director | Buy | +30,000 | +$25.34K |
| 2026-02-13 | Jared Kelly | Chief Executive Officer | Buy | +35,100 | +$29.52K |
| 2026-02-13 | Kirk Look | Chief Financial Officer | Buy | +12,000 | +$10.10K |
| 2026-02-13 | Patricia S Andrews | Director | Buy | +35,400 | +$30.29K |
| 2026-02-13 | Allison Hagerman | VP, Product Development | Buy | +10,000 | +$8.30K |
| 2026-01-20 | Bernd R. Seizinger | Director | Buy | +100,000 | +$103.77K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bernd R. Seizinger | Director | 566,991 | $268.30K |
| Wayne Pisano | Director | 492,414 | $233.01K |
| Kirk Look | Chief Financial Officer | 287,515 | $136.05K |
| Thomas Charles Heineman | Chief Medical Officer | 282,818 | $133.83K |
| Allison Hagerman | Chief Technology Officer | 115,059 | $54.45K |
| Jared Kelly | Chief Executive Officer | 114,050 | $53.97K |
| Deborah Margaret Brown | Director | 109,851 | $51.98K |
| Patricia S Andrews | Director | 78,128 | $36.97K |
| Andrew Aromando | Chief Business Officer | 55,100 | $26.07K |
| James T. Parsons | Director | 41,849 | $19.80K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ONCY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.